Literature DB >> 1525779

The effects of adjuvant chemotherapy on growth in children with medulloblastoma.

J S Olshan1, J Gubernick, R J Packer, G J D'Angio, J W Goldwein, S M Willi, T Moshang.   

Abstract

BACKGROUND: Current therapy for children with medulloblastoma includes craniospinal radiation therapy (CSRT) with or without adjuvant chemotherapy. The difference in growth of children after the two different therapeutic modalities is unknown.
METHODS: The growth of 38 prepubertal children who survived medulloblastoma was reviewed retrospectively. Fifteen of these patients received CSRT alone; 23 received chemotherapy in addition to the radiation therapy.
RESULTS: The average growth velocity of all patients with medulloblastoma during the 4 years of the study was below the mean for age and sex in all patients except one. Most patients grew at velocities more than two standard deviations below the mean. The overall growth of children who received chemotherapy in conjunction with CSRT was significantly worse than the growth of those who received only CSRT. The children who received chemotherapy showed little or no improvement in growth velocity by year 4; those who did not receive chemotherapy had some improvement.
CONCLUSIONS: These findings suggest that chemotherapy potentiates the deleterious effects of radiation on growth.

Entities:  

Mesh:

Year:  1992        PMID: 1525779     DOI: 10.1002/1097-0142(19921001)70:7<2013::aid-cncr2820700734>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Bone growth mechanisms and the effects of cytotoxic drugs.

Authors:  H Robson
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?

Authors:  S Dupuis-Girod; O Hartmann; E Benhamou; F Doz; F Mechinaud; E Bouffet; C Coze; C Kalifa
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

Review 3.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

Review 4.  A systematic review of selected musculoskeletal late effects in survivors of childhood cancer.

Authors:  Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Karen Wasilewski-Masker; Louis S Constine; Leslie L Robison; Kirsten K Ness
Journal:  Curr Pediatr Rev       Date:  2014

5.  Hormonal dysfunction is frequent in cancer survivors treated with radiotherapy to the head and neck region.

Authors:  Mette Seland; Trine Bjøro; Torbjørn Furre; Thomas Schreiner; Jens Bollerslev; Sophie Dorothea Fosså; Jon Håvard Loge; Harald Holte; Cecilie Essholt Kiserud
Journal:  J Cancer Surviv       Date:  2015-03-07       Impact factor: 4.442

6.  Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma.

Authors:  Bree R Eaton; Natia Esiashvili; Sungjin Kim; Briana Patterson; Elizabeth A Weyman; Lauren T Thornton; Claire Mazewski; Tobey J MacDonald; David Ebb; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Neuro Oncol       Date:  2015-12-19       Impact factor: 12.300

Review 7.  Chemotherapy for medulloblastomas and primitive neuroectodermal tumors.

Authors:  B H Cohen; R J Packer
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

8.  Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy.

Authors:  Weizhen Xu; Anna Janss; Roger J Packer; Peter Phillips; Joel Goldwein; Thomas Moshang
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

9.  Growth and puberty after growth hormone treatment after irradiation for brain tumours.

Authors:  A L Ogilvy-Stuart; S M Shalet
Journal:  Arch Dis Child       Date:  1995-08       Impact factor: 3.791

10.  Endocrine sequelae of cancer and cancer treatments.

Authors:  Charles J Stava; Camilo Jimenez; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2007-11-20       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.